⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312579 | 0.82 | CHRM2 (0.42) | — | |
| SCHEMBL23761859 | 0.80 | CHRM2 (0.52) | — | |
| SCHEMBL15471203 | 0.79 | KDM4E (0.38) | — | |
| SCHEMBL22752564 | 0.78 | CHRM2 (0.56) | — | |
| SCHEMBL23761801 | 0.78 | CHRM2 (0.56) | — | |
| SCHEMBL14350170 | 0.75 | — | — | |
| SCHEMBL24515163 | 0.75 | CHRM2 (0.52) | — | |
| SCHEMBL6366413 | 0.75 | — | — | |
| SCHEMBL17211409 | 0.73 | — | — | |
| SCHEMBL12619778 | 0.73 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-11806323-B2 | Topical anesthetics | PTC Innovations, LLC (US) | 2023-11-07 | — | — | US | disclosed |
| US-20200331910-A1 | Mammalian and Bacterial Nitric Oxide Synthase Inhibitors | UNIV NORTHWESTERN (US) | 2020-10-22 | — | — | US | disclosed |
| US-10759791-B2 | Mammalian and bacterial nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3223822-B1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS | ENANTA PHARM INC (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20180188428-A1 | NEAR-INFRARED CUT FILTER, METHOD FOR PRODUCING NEAR-INFRARED CUT FILTER, AND SOLID-STATE IMAGING ELEMENT | FUJIFILM CORPORATION (JP) | 2018-07-05 | — | — | US | disclosed |
| US-9957267-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957267-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20130237519-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-09-12 | — | — | US | disclosed |
| US-20130237519-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-09-12 | — | — | US | disclosed |
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-09 | — | — | US | disclosed |
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| EP-0875501-B1 | Alkylenediamine derivative, anti-ulcer drug, and antibacterial drug | SHISEIDO CO LTD (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-6001880-A | DISUBSTITUTED N-(2-DIALKYLAMINOETHYL)BENZAMIDE DERIVATIVES OF GIVEN FORMULA; ANTIBACTERIAL ACTIVITY AGAINST HELICOBACTER PYROLI, ADMINISTERING FOR THE PREVENTION OR CURE OF PEPTIC ULCERS | SHISEIDO CO., LTD. (JP) | 1999-12-14 | — | — | US | disclosed |
| EP-0875501-A2 | Alkylenediamine derivative, anti-ulcer drug, and antibacterial drug | SHISEIDO COMPANY LIMITED (JP) | 1998-11-04 | — | — | EP | disclosed |